CXCR1 as a novel target for directing reactive T cells toward melanoma: Implications for adoptive cell transfer immunotherapy

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1833-1847

  Sapoznik, Sivan ^a   Ortenberg, Rona ^a,b   Galore Haskel, Gilli ^a,b   Kozlovski, Stav ^a,b   Levy, Daphna ^a   Avivi, Camila ^a   Barshack, Iris ^a,b   Cohen, Cyrille J ^c   Besser, Michal J ^a,b   Schachter, Jacob ^a   Markel, Gal ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

Chemotaxis; CXCR1; Immunotherapy; Melanoma; T cell

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 8;

ADOPTIVE TRANSFER; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE MIGRATION; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ANTIBODIES, NEUTRALIZING; CELL MOVEMENT; CHEMOKINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; RECEPTORS, INTERLEUKIN-8A; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84867577248     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1245-1     Document Type: Article

References (58)

1. Vicari AP, Caux C (2002) Chemokines in cancer. Cytokine Growth Factor Rev 13:143-154
2. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M et al (2009) Chemokine expression in melanoma metastases associated with CD8? T-cell recruitment. Cancer Res 69:3077-3085
3. Viola A, Molon B, Contento RL (2008) Chemokines: coded messages for T-cell missions. Front Biosci 13:6341-6353
4. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540-550
5. Jin T, Xu X, Hereld D (2008) Chemotaxis, chemokine receptors and human disease. Cytokine 44:1
6. Zhang T, Somasundaram R, Berencsi K, Caputo L, Gimotty P et al (2006) Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol 36:457-467
7. Kunz M, Toksoy A, Goebeler M, Engelhardt E, Brocker E et al (1999) Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J Pathol 189:552-558
8. Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P et al (2005) CXC Chemokine Ligand 12 (Stromal Cell-Derived Factor 1-±) and CXCR4-Dependent Migration of CTLs toward Melanoma Cells in Organotypic Culture. J Immunol 174:5856
9. Vianello F, Papeta N, Chen T, Kraft P, White N et al (2006) Murine B16 Melanomas Expressing High Levels of the Chemokine Stromal-Derived Factor-1/CXCL12 Induce Tumor-Specific T Cell Chemorepulsion and Escape from Immune Control. J Immunol 176:2902
10. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R et al (2008) Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. J Clin Oncol 26:5233
11. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357
12. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299-308
13. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J et al (2006) Phase I study of adoptive T-cell therapy using antigenspecific CD8? T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24:5060-5069
14. Khammari A, Labarriere N, Vignard V, Nguyen JM, Pandolfino MC et al (2009) Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol 129:2835-2842
15. Brimnes MK, Gang AO, Donia M, Thor Straten P, Svane IM, et al. (2012) Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion. Cancer Immunol Immunother
16. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF et al (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173:7125-7130
17. Zhou J, Dudley ME, Rosenberg SA, Robbins PF (2005) Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28:53-62
18. Peterson AC, Harlin H, Gajewski TF (2003) Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21:2342-2348
19. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L et al (1997) Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3:37-44
20. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563-570
21. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC et al (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8 ? T cells in patients with melanoma. J Immunol 175:6169-6176
22. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129
23. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-546
24. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-240
25. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y et al (2010) Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 16:5458-5468
26. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS et al (1989) Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7:250-261
27. Gajewski TF (2007) Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13:5256-5261
28. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A et al (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213:131
29. Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC et al (2009) Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 126:186-200
30. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O et al (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16:2646-2655
31. Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O et al (2006) Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol 177:6062-6071
32. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, et al. (2010) Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immunother 59(2):215-230
33. Svec J, Ergang P, Mandys V, Kment M, Pacha J (2010) Expression profiles of proliferative and antiapoptotic genes in sporadic and colitis-related mouse colon cancer models. Int J Exp Pathol 91:44-53
34. Orchard PJ, Blazar BR, Burger S, Levine B, Basso L et al (2002) Clinical-scale selection of anti-CD3/CD28-Activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Hum Gene Ther 13:979-988
35. Bialer G, Horovitz-Fried M, Ya'acobi S, Morgan RA, Cohen CJ (2010) Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol 184:6232-6241
36. Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC et al (2006) High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 13:151-159
37. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O et al (2009) Minimally cultured or selected autologous tumorinfiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother 32:415-423
38. Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A et al (2010) Enrichment of Foxp3? CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 185:6734-6740
39. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL et al (2002) Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 13:1971-1980
40. Hess C, Means TK, Autissier P, Woodberry T, Altfeld M et al (2004) IL-8 responsiveness defines a subset of CD8 T cells poised to kill. Blood 104:3463-3471
41. Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC et al (2009) Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 23:267-275
42. Ludwig A, Petersen F, Zahn S, Gotze O, Schroder JM et al (1997) The CXC-chemokine neutrophil-Activating peptide-2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin-8 receptors CXCR-1 and CXCR-2. Blood 90:4588-4597
43. Rajagopalan L, Rajarathnam K (2004) Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain. J Biol Chem 279:30000-30008
44. Gasser O, Missiou A, Eken C, Hess C (2005) Human CD8? T cells store CXCR1 in a distinct intracellular compartment and upregulate it rapidly to the cell surface upon activation. Blood 106:3718-3724
45. Gasser O, Schmid TA, Zenhaeusern G, Hess C (2006) Cyclooxygenase regulates cell surface expression of CXCR3/1-storing granules in human CD4? T cells. J Immunol 177:8806-8812
46. Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A et al (2010) Enrichment of Foxp3? CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 185:6734-6740
47. Shioda T, Nakayama EE, Tanaka Y, Xin X, Liu H et al (2001) Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5. J Virol 75:3462-3468
48. Quereux G, Pandolfino MC, Knol AC, Khammari A, Volteau C et al (2007) Tissue prognostic markers for adoptive immunotherapy in melanoma. Eur J Dermatol 17:295-301
49. Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J et al (2003) Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol 170:2161-2169
50. Richmond A, Thomas HG (1988) Melanoma growth stimulatory activity: isolation from human melanoma tumors and characterization of tissue distribution. J Cell Biochem 36:185-198
51. Rofstad EK, Halsor EF (2000) Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 60:4932-4938
52. Cheong HS, Shin HD, Lee SO, Park BL, Choi YH et al (2006) Polymorphisms in interleukin 8 and its receptors (IL8, IL8RA and IL8RB) and association of common IL8 receptor variants with peripheral blood eosinophil counts. J Hum Genet 51:781
53. Dumitrascu D (1996) Mast cells as potent inflammatory cells. Rom J Intern Med 34:159-172
54. Chuntharapai A, Lee J, Hebert CA, Kim KJ (1994) Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol 153:5682-5688
55. Inngjerdingen M, Damaj B, Maghazachi AA (2001) Expression and regulation of chemokine receptors in human natural killer cells. Blood 97:367-375
56. Smith ML, Olson TS, Ley K (2004) CXCR2- and E-selectininduced neutrophil arrest during inflammation in vivo. J Exp Med 200:935-939
57. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y et al (2010) Transduction of tumor-specific T Cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 16:5458-5468
58. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV et al (2008) Virus-specific T cells engineered to coexpress tumorspecific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264-1270